HLAVNÍ TÉMA Sekvenování a kombinace terapií při kardio-reno-metabolickém syndromu: GLP-1 RA, SGLT2 inhibitory, hypolipidemika a antagonisté mineralokortikoidních receptorů 394 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék. 2026;72(6):388-394 / www.casopisvnitrnilekarstvi.cz 13. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117–S314. 14. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2026 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Public Review Draft, March 2026. [Internet]. Available from: <https://kdigo.org>. 15. Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-4140. 16. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF). N Engl J Med. 2023;389(12):1069-1084. 17. Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes (STEP-HFpEF DM). N Engl J Med. 2024;390(15):1394-1407. 18. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT). N Engl J Med. 2025;392(5):427-437. 19. Shokravi A, Seth J, Mancini GBJ. Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis. Cardiovasc Diabetol. 2025;24(1):370. 20. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/ AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2026; doi: 10.1016/j.jacc.2025. 11. 016. 21. Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC/ EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359-4378. 22. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (IMPROVE-IT). N Engl J Med. 2015;372(25):2387-2397. 23. Kim BK, Hong SJ, Lee YJ, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with ASCVD (RACING). Lancet. 2022;400(10349):380-390. 24. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (FOURIER). N Engl J Med. 2017;376(18):1713-1722. 25. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (ODYSSEY OUTCOMES). N Engl J Med. 2018;379(22):2097-2107. 26. O’Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease (FOURIER-OLE). Circulation. 2022;146(15):1109-1119. 27. Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol (ORION-10 and ORION-11). N Engl J Med. 2020;382(16):1507-1519. 28. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients (CLEAR Outcomes). N Engl J Med. 2023;388(15):1353-1364. 29. Khine MT, De P, Frankel AH, et al. Consensus Statement: Finerenone in the Management of Diabetes Kidney Disease (ABCD/UKKA). Br J Diabetes. 2024;24(2):1-14. 30. Neuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnott C, et al. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024;149(6):450-462. 31. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-3639. 32. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865. 33. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-1289. 34. Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (IRIS). N Engl J Med. 2016;374(14):1321-1331. ODBORNÝ GARANT: MUDr. Pavel Rutar Interní oddělení, Nemocnice Na Homolce, Praha POŘADATEL: Společnost SOLEN, s. r. o., ve spolupráci s Interním oddělením, Nemocnice Na Homolce POČET KREDITŮ 2 Registrace ZDARMA TERMÍN prosinec 2025 až listopad 2026 dostupný na online.solen.cz ON LINE KURZ ODBORNÝ PROGRAM Závratě z pohledu ORL lékaře MUDr. Vladimír Koucký, Ph.D. Algoritmy diagnostiky a léčby závrativých stavů doc. MUDr. Jaroslav Jeřábek, CSc. Poruchy stability u pacientů s benigním paroxysmálním polohovým vertigem doc. PhDr. Ondřej Čakrt, Ph.D., doc. MUDr. Jaroslav Jeřábek, CSc. Nevestibulárne závraty – prof. MUDr. Egon Kurča, Ph.D. Závratě z pohledu ORL lékaře ZLATÝ PARTNER
RkJQdWJsaXNoZXIy NDA4Mjc=